IT1245748B - Preparazione includente anticorpi monoclonali biotinilati, avidina e biotina, per la diagnosi di affezioni tumorali e suo impiego - Google Patents

Preparazione includente anticorpi monoclonali biotinilati, avidina e biotina, per la diagnosi di affezioni tumorali e suo impiego

Info

Publication number
IT1245748B
IT1245748B IT06805390A IT6805390A IT1245748B IT 1245748 B IT1245748 B IT 1245748B IT 06805390 A IT06805390 A IT 06805390A IT 6805390 A IT6805390 A IT 6805390A IT 1245748 B IT1245748 B IT 1245748B
Authority
IT
Italy
Prior art keywords
biotinylate
avidin
biotin
diagnosis
monoclonal antibodies
Prior art date
Application number
IT06805390A
Other languages
English (en)
Other versions
IT9068053A0 (it
IT9068053A1 (it
Inventor
Giovanni Paganelli
Antonio Siccardi
Massimo Malcovati
Gianalfredo Scassellati
Ferruccio Fazio
Original Assignee
Mini Ricerca Scient Tecnolog
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mini Ricerca Scient Tecnolog filed Critical Mini Ricerca Scient Tecnolog
Priority to IT06805390A priority Critical patent/IT1245748B/it
Publication of IT9068053A0 publication Critical patent/IT9068053A0/it
Priority to EP91121419A priority patent/EP0496074B1/en
Priority to DE69123235T priority patent/DE69123235T2/de
Publication of IT9068053A1 publication Critical patent/IT9068053A1/it
Application granted granted Critical
Publication of IT1245748B publication Critical patent/IT1245748B/it

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6891—Pre-targeting systems involving an antibody for targeting specific cells
    • A61K47/6897—Pre-targeting systems with two or three steps using antibody conjugates; Ligand-antiligand therapies
    • A61K47/6898—Pre-targeting systems with two or three steps using antibody conjugates; Ligand-antiligand therapies using avidin- or biotin-conjugated antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
    • A61K47/6911—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome
    • A61K47/6913—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome the liposome being modified on its surface by an antibody
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2123/00—Preparations for testing in vivo

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nanotechnology (AREA)
  • Biotechnology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Molecular Biology (AREA)
  • Medical Informatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Dispersion Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
IT06805390A 1990-12-21 1990-12-21 Preparazione includente anticorpi monoclonali biotinilati, avidina e biotina, per la diagnosi di affezioni tumorali e suo impiego IT1245748B (it)

Priority Applications (3)

Application Number Priority Date Filing Date Title
IT06805390A IT1245748B (it) 1990-12-21 1990-12-21 Preparazione includente anticorpi monoclonali biotinilati, avidina e biotina, per la diagnosi di affezioni tumorali e suo impiego
EP91121419A EP0496074B1 (en) 1990-12-21 1991-12-13 Biotinylated monoclonal antibodies, avidin and biotin for diagnosis and therapy
DE69123235T DE69123235T2 (de) 1990-12-21 1991-12-13 Biotinylierte monoklonale Antikörper, Avidin und Biotin für die Diagnose und Therapie

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IT06805390A IT1245748B (it) 1990-12-21 1990-12-21 Preparazione includente anticorpi monoclonali biotinilati, avidina e biotina, per la diagnosi di affezioni tumorali e suo impiego

Publications (3)

Publication Number Publication Date
IT9068053A0 IT9068053A0 (it) 1990-12-21
IT9068053A1 IT9068053A1 (it) 1992-06-22
IT1245748B true IT1245748B (it) 1994-10-14

Family

ID=11307501

Family Applications (1)

Application Number Title Priority Date Filing Date
IT06805390A IT1245748B (it) 1990-12-21 1990-12-21 Preparazione includente anticorpi monoclonali biotinilati, avidina e biotina, per la diagnosi di affezioni tumorali e suo impiego

Country Status (3)

Country Link
EP (1) EP0496074B1 (it)
DE (1) DE69123235T2 (it)
IT (1) IT1245748B (it)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6416738B1 (en) 1973-12-07 2002-07-09 Neorx Corporation Pretargeting methods and compounds
WO1993025240A2 (en) * 1992-06-09 1993-12-23 Neorx Corporation Pretargeting methods and compounds
US6075010A (en) * 1992-06-09 2000-06-13 Neorx Corporation Small molecular weight ligand-hexose containing clearing agents
US5525338A (en) * 1992-08-21 1996-06-11 Immunomedics, Inc. Detection and therapy of lesions with biotin/avidin conjugates
US6358490B2 (en) 1992-06-09 2002-03-19 Neorx Corporation Three-step pretargeting methods and compounds
US6217869B1 (en) 1992-06-09 2001-04-17 Neorx Corporation Pretargeting methods and compounds
US5578287A (en) * 1992-06-09 1996-11-26 Neorx Corporation Three-step pretargeting methods using improved biotin-active agent
US6022966A (en) * 1993-11-22 2000-02-08 Neorx Corporation Pretargeting methods and compounds
US5911969A (en) * 1992-06-09 1999-06-15 Neorx Corporation Pretargeting protocols for enhanced localization of active agents to target sites
US5914312A (en) * 1992-06-09 1999-06-22 Neorx Corporation Pretargeting methods and compounds
US5976535A (en) * 1992-06-09 1999-11-02 Neorx Corporation Pretargeting protocols for the enhanced localization of cytotoxins to target sites and cytotoxic combinations useful therefore
US5624896A (en) * 1992-06-09 1997-04-29 Neorx Corporation Clearing agents useful in pretargeting methods
US5541287A (en) * 1992-06-09 1996-07-30 Neorx Corporation Pretargeting methods and compounds
US5616690A (en) * 1992-06-09 1997-04-01 Neorx Corporation Hexose derivatized human serum albumin clearing agents
GB9300686D0 (en) * 1993-01-15 1993-03-03 Imp Cancer Res Tech Compounds for targeting
GB2300859B (en) * 1993-01-15 1997-06-18 Imp Cancer Res Tech Compounds comprising a target cell-specific portion and a further portion
IL108388A0 (en) * 1993-01-21 1994-04-12 Harvard College Amplified direction of effector groups to specific target cells in an animal
US5482698A (en) * 1993-04-22 1996-01-09 Immunomedics, Inc. Detection and therapy of lesions with biotin/avidin polymer conjugates
US6120768A (en) * 1993-05-17 2000-09-19 Immunomedics, Inc. Dota-biotin derivatives
IL109666A0 (en) * 1993-05-17 1994-08-26 Immunomedics Inc A targeting composition containing a biotin- or avidinprotein conjugate and methods for the use thereof
WO1995015978A1 (en) * 1993-12-07 1995-06-15 Neorx Corporation Pretargeting methods and compounds
US6015897A (en) * 1993-12-07 2000-01-18 Neorx Corporation Biotinamido-n-methylglycyl-seryl-o-succinamido-benzyl dota
CA2178476A1 (en) * 1993-12-07 1995-06-15 Neorx Corporation Pretargeting methods and compounds
WO1995015770A1 (en) * 1993-12-09 1995-06-15 Neorx Corporation Pretargeting methods and compounds
IL112372A (en) * 1994-02-07 2001-08-26 Res Dev Foundation Non-viral vector for the delivery of genetic information to cells
US6172045B1 (en) 1994-12-07 2001-01-09 Neorx Corporation Cluster clearing agents
US6908903B1 (en) 1994-12-07 2005-06-21 Aletheon Pharmaceuticals, Inc. Cluster clearing agents
US5955605A (en) * 1995-02-21 1999-09-21 Neorx Corporation Biotinidase resistant biotin-DOTA conjugates
EP0840797B1 (en) * 1995-07-25 2014-09-03 Crucell Holland B.V. Methods and means for targeted gene delivery
JP2000515364A (ja) * 1996-03-30 2000-11-21 サイエンス パーク ラフ ソチエタ ペル アツィオニ 標識した活性化腫瘍特異的ｔ細胞の生産方法および腫瘍療法におけるそれらの使用
US7011812B1 (en) 1996-05-03 2006-03-14 Immunomedics, Inc. Targeted combination immunotherapy of cancer and infectious diseases
IT1289728B1 (it) 1996-12-10 1998-10-16 Sorin Biomedica Cardio Spa Dispositivo di impianto e corredo che lo comprende
US7144991B2 (en) 1999-06-07 2006-12-05 Aletheon Pharmaceuticals, Inc. Streptavidin expressed gene fusions and methods of use thereof
IT1317835B1 (it) 2000-02-15 2003-07-15 San Raffaele Centro Fond Citochine modificate per uso nella terapia del cancro.
US7309694B2 (en) 2000-02-15 2007-12-18 Fondazione Centro San Raffaele Del Monte Tabor Modified cytokines for use in cancer therapy
US7109303B2 (en) 2000-02-15 2006-09-19 Fondazione Centro San Raffaele Del Monte Tabor Modified cytokines for use in cancer therapy
EP1351712B1 (en) 2000-06-20 2007-08-01 Immunomedics, Inc. Targeted combination immunotherapy of cancer and infectious diseases
ITRM20010079A1 (it) 2001-02-16 2002-08-16 Sigma Tau Ind Farmaceuti Amminoderivati della biotina e loro coniugati con chelanti macrociclici.
GB0209896D0 (en) * 2002-04-30 2002-06-05 Molmed Spa Conjugate
ITRM20030196A1 (it) 2003-04-24 2004-10-25 Sigma Tau Ind Farmaceuti Uso di reagenti per la preparazione di un medicamento
AU2008235566B2 (en) 2007-04-04 2013-06-06 Alfasigma S.p.A Anti-EpCAM antibody and uses thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1987002893A1 (en) * 1985-11-18 1987-05-21 Board Of Regents, The University Of Texas System Polychelating agents for image and spectral enhancement (and spectral shift)
US4863713A (en) * 1986-06-23 1989-09-05 The Board Of Trustees Of Leland Stanford Jr. Univ. Method and system for administering therapeutic and diagnostic agents

Also Published As

Publication number Publication date
IT9068053A0 (it) 1990-12-21
EP0496074B1 (en) 1996-11-20
DE69123235T2 (de) 1997-06-05
EP0496074A1 (en) 1992-07-29
DE69123235D1 (de) 1997-01-02
IT9068053A1 (it) 1992-06-22

Similar Documents

Publication Publication Date Title
IT1245748B (it) Preparazione includente anticorpi monoclonali biotinilati, avidina e biotina, per la diagnosi di affezioni tumorali e suo impiego
EP0597829A4 (en) NEW MONOCLONAL ANTIBODY DRESSES AGAINST A NEW ANTIGEN ASSOCIATED WITH HUMAN TUMORS.
KR880700061A (ko) 인체 암종양과 관련된 항원에 대한 단클론성 항체
DE69319662D1 (de) Monoklonale Antikörper gegen GP130-Protein
IT8320550A0 (it) Procedimento di purificazione peraffinita' in cui si impiegano anticorpi monoclonali.
IT8319234A0 (it) Procedimento per la produzione di anticorpi monoclonali umani.
HUP0200537A2 (en) Monoclonal antibodies, antigens and diagnosis and therapy of malignant diseases
DE3783277D1 (de) Monoklonaler antikoerper gegen humanes lungenkarzinom.
DE3854502D1 (de) Gegen hiv-antigene spezifischer monoklonaler antikörper.
IT1207589B (it) Composizione di anticorpi monoclonali umani cross-protettivi.
DE3885355D1 (de) Monoklonale Antikörper.
FR2631239B1 (fr) Anticorps monoclonal humain et hybridome le produisant
EP0460607A3 (en) Novel monoclonal antibody to novel antigen associated with human tumors
AU8866791A (en) Monoclonal antibody for use in diagnosing alzheimer's disease, hybridoma secreting said antibody and preparation method therefor
KR890700358A (ko) 인체 종양관련 항원
IL94912A0 (en) Monoclonal antibodies involved in alzheimer's disease,hybridomas secreting these monoclonal antibodies,antigen recognized by these antibodies,and their application
DK69690A (da) Humane anti-rh(d) monoklonale antistoffer
DK717888D0 (da) Monoklonale antistoffer
NO174110C (no) Monoklonalt antistoff til anvendelse in vitro for diagnose av maligne tumor- eller akutte inflammasjonssykdommer, og som er spesifikt for N-acetyl-neuraminsyre i hybridom som produserer antistoffet
DK69590D0 (da) Humane anti-rh(d) monoklonale antistoffer
DE3785795D1 (de) Monoklonale anti-menschliche magenkrebs-antikoerper.
IT1239065B (it) Anticorpo monoclonale che inibisce l'azione biologica del fattore piastrinico 4
FI952171A0 (fi) Hepatiitti B-pinta-antigeeneille aktiivisten ihmisen monoklonaalisten vasta-aineiden tuotto
DE69129582D1 (de) Antikörper gegen menschlichen plasmin-alpha 2-plasmininhibitor-komplex, hybridoma und immunoassay
DE3787239D1 (de) Komplementabhängiger zytolytischer monoklonaler Antikörper gegen Trichomonas vaginalis und seine therapeutische und diagnostische Verwendung.

Legal Events

Date Code Title Description
0001 Granted
TA Fee payment date (situation as of event date), data collected since 19931001

Effective date: 19981231